Royalty Pharma
RPRX
56.76
+0.32
+0.57%
Royalty Pharma
US · RPRX
#759 by market cap
Listed 2020
56.76
+0.32
+0.57%
Live - 5344 symbols - heartbeat 475s ago
· 2026-10-08 07:37
Pre-market
56.57
-0.33%
After-hours
56.76
0.00%
- Market cap
- 25.27B
- P/E (TTM)i
- 30.52
- P/Bi
- 3.70
- EPSi
- 1.78
- Div yieldi
- 1.60%
- 52W posi
- 74%
Reader sentiment
Are you bullish or bearish on RPRX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 5 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.8 percentage points.
Institutional ownership
- Held by institutions
- 84.97% -0.78pp
- Institutions
- 810 -5
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund72.43%
Individual/Insider6.10%
Hedge Fund5.40%
Public Company2.50%
Government Pension Fund1.56%
Sovereign Wealth Fund1.26%
Private Company1.03%
Family Office/Trust0.28%
Insurance Company0.21%
Other9.23%
Top holders as of 2026-06-30
Capital Research
10.70% · 47.65M sh
Morgan Stanley Investment Management Inc.
8.38% · 37.31M sh
BlackRock
6.25% · 27.83M sh
Mario Giuliani
4.80% · 21.37M sh
FMR
4.32% · 19.22M sh
State Street Global Advisors
2.77% · 12.34M sh
T. Rowe Price Group, Inc.
2.51% · 11.19M sh
Swedbank Robur Fonder AB
2.41% · 10.73M sh
Baillie Gifford
2.25% · 10.02M sh
Geode Capital Management, LLC
1.81% · 8.06M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 23 buys · 27 sells
| Name | Role | Stake |
|---|---|---|
| Mario Giuliani | Director | 4.80% |
| Pablo Legorreta | Founder, Chairman of the Board & CEO | 1.10% |
| Christopher Hite | Vice Chairman & Executive VP | 0.07% |
| Gregory Norden | Independent Director | 0.04% |
| Bonnie Bassler | Independent Director | 0.02% |
| Errol De Souza | Independent Director | 0.01% |
| Ted Love | Independent Director | 0.01% |
| Catherine Engelbert | Independent Director | 0.01% |
| Terrance Coyne | Chief Financial Officer | 0.01% |
| David Hodgson | Independent Director | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-04 | Marshall Urist | Executive VP and Head of Research & Investments | Automatic Disposition | -4,126 | $57.10 |
| 2026-09-29 | Bonnie Bassler | Independent Director | Other Acquisition | +642 | $58.41 |
| 2026-09-27 | Marshall Urist | Executive VP and Head of Research & Investments | Automatic Disposition | -4,126 | $57.88 |
| 2026-09-21 | Christopher Hite | Vice Chairman & Executive VP | Automatic Disposition | -100,000 | $58.51–58.93 |
| 2026-08-18 | Christopher Hite | Vice Chairman & Executive VP | Other Disposition | -16,800 | -- |
| 2026-08-17 | Christopher Hite | Vice Chairman & Executive VP | Automatic Disposition | -100,000 | $59.97 |
| 2026-08-12 | Terrance Coyne | Chief Financial Officer | Automatic Disposition | -11,002 | $58.59–59.14 |
| 2026-08-06 | Marshall Urist | Executive VP and Head of Research & Investments | Other Derivative Disposition | -3,000 | -- |
| 2026-08-06 | Terrance Coyne | Chief Financial Officer | Other Disposition | -18,500 | -- |
| 2026-08-06 | Pablo Legorreta | Founder, Chairman of the Board & CEO | Other Derivative Disposition | -30,000 | -- |
| 2026-08-04 | Christopher Hite | Vice Chairman & Executive VP | Other Acquisition | +11,002 | -- |
| 2026-08-04 | Marshall Urist | Executive VP and Head of Research & Investments | Other Acquisition | +8,252 | -- |
| 2026-08-04 | Terrance Coyne | Chief Financial Officer | Other Acquisition | +11,002 | -- |
| 2026-08-04 | Pablo Legorreta | Founder, Chairman of the Board & CEO | Other Acquisition | +65,216 | -- |
| 2026-06-30 | Marshall Urist | Executive VP and Head of Research & Investments | Automatic Disposition | -9,099 | $55.88 |
| 2026-06-29 | Christopher Hite | Vice Chairman & Executive VP | Automatic Disposition | -130,000 | $56.44–57.10 |
| 2026-06-29 | Bonnie Bassler | Independent Director | Other Acquisition | +689 | $54.40 |
| 2026-06-23 | Marshall Urist | Executive VP and Head of Research & Investments | Automatic Disposition | -9,098 | $55.18 |
| 2026-06-22 | Christopher Hite | Vice Chairman & Executive VP | Automatic Disposition | -150,000 | $54.11–54.47 |
| 2026-06-04 | David Hodgson | Independent Director | Other Acquisition | +4,545 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:37:27 · For reference only, not investment advice and not tailored to your situation.